NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism.

NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.

The main application is the engineering of recombinant proteins like antibodies or enzymes for better therapies.

NanoMedSyn

Org chart

Teams

Offices